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bronchodilator FEV1% pred, number of hospital admissions and
ER visits in the year prior to baseline, number of concomitant
diagnoses and BMI were independently associated with EQ-5D
utility. Danish, Spanish and Dutch patients had signiﬁcantly
higher utilities than US patients. French patients had lower util-
ities. Utilities calculated with the US value set were on average
5% higher than utilities calculated with the UK set. CONCLU-
SIONS: Increasing severity of COPD was associated with signif-
icant decline of EQ-5D VAS scores and utilities. These results
demonstrate that a generic instrument can assess COPD impact
on quality of life and that the scores discriminate between
patients groups of known severity. These utilities will be useful
in cost-effectiveness assessments.
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OBJECTIVE: To develop and validate a self-reported question-
naire measuring the severity of dyspnoea and its impact on daily
life. METHODS: A list of daily life activities was selected by the
Scientiﬁc Committee (SC) after an extensive literature review.
This selection was tested during ﬁve interviews with respiratory
physicians, resulting in a modiﬁed list and a preliminary grading
system assessing how dyspnoea impacts on activities. After in-
depth interviews conducted with ten mild-to-severe COPD
patients, a test questionnaire was developed. Six new patients
completed the test questionnaire and commented its contents and
format. Two response choice formats (multiple or exclusive
response) were tested to describe the impact of dyspnoea on
activities. In addition, four new clinicians completed a standard
form evaluating the questionnaire after having used it in clinical
practice with four of their patients. The questionnaire was
revised according to all comments received. RESULTS: Five con-
cepts (self-care, physiological activities, activities at home, activ-
ities outside, and sport) and 48 activities were ﬁrst identiﬁed.
After clinician and patient interviews, some activities were
grouped, split, suppressed or added. The test questionnaire had
20 items. The recall period was set to a week. The descriptive
criteria of the impact of dyspnoea on activities were: abandoned,
slowed, need for pause, need for help, activities modiﬁed,
avoided. After the cognitive debrieﬁng and comments from both
patients and clinicians, the ﬁnal format was established as a mix
of the two tested formats. CONCLUSION: This pilot question-
naire assessing the impact of dyspnoea on COPD patients activ-
ities in real life was well accepted by both patients and doctors.
Further validation is needed to support its use and guide inter-
pretation in clinical practice and clinical trials.
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BACKGROUND: Cough and sputum are leading symptoms of
chronic (obstructive) bronchitis. It is acknowledged that these
symptoms impact patients’ lives, yet they have never been mea-
sured adequately. OBJECTIVE: To develop a self-administered
instrument in ﬁve countries (seven languages) that captures con-
cepts relevant to chronic (obstructive) bronchitis patients who
suffer from cough and sputum. METHODS: After literature
review and appraisal of existing instruments, a conceptual model
was developed and then reviewed by clinical respiratory experts.
Thirty extensive face-to-face concept elicitation interviews were
conducted with patients in ﬁve countries (France, Germany,
Japan, Spain, US). After transcription and domain-mapping of
the interviews in each country, an international item generation
meeting was conducted and a draft questionnaire was simulta-
neously created in ﬁve languages. After clinical expert review,
testing for face and content validity was performed in cognitive
debrieﬁngs in seven languages in six countries with 35 patients
(English for US/UK, French, German, Japanese, and Spanish for
US/Spain). RESULTS: The conceptual model addressed symp-
toms of cough and sputum and their respective impact. The
resulting questionnaire, Cough and Sputum Assessment Ques-
tionnaire (CASA-Q), has 25 items with 6 items for symptoms (3
cough, 3 sputum) and 19 items for the impact of these symp-
toms (12 cough, 7 sputum). The response choices per item
consist of ﬁve options from “never” to “always” or “not at all”
to “extremely”, depending on the context of the item. Due to its
simultaneous item generation in ﬁve languages and ﬁeld testing
in seven languages, item wording overall is following a simple
sentence structure. The ease of understanding and relevance of
each question was found acceptable across languages. CON-
CLUSION: The CASA-Q is a well-developed, patient-based
questionnaire relevant to the assessment of chronic bronchitis.
The CASA-Q, after completion of psychometric validation, may
contribute to a comprehensive patient-centered assessment.
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OBJECTIVES: Analize the patient satisfaction with COPD treat-
ment, and relation with different drugs. METHODS: Cross-
sectional study of 377 patients with COPD controlled in three
primary care settings. Non-random sample: patients were cited
in the health centers and were asked to answer 10 questions
about satisfaction with their treatment (positive scale 1–7). In
this interview the investigators carried out a spirometry. Other
variables measured were: age, sex, comorbidity, and prescribed
treatment. RESULTS: 331 (87.8%) males, age (mean + std) 67.7
+ 8.6 years, 53% had at least another comorbid condition; FEV
1 58% + 21%. In 63 patients (15%) we couldn’t ﬁnd any pre-
scribed treatment. 65% remaining received treatment with:
ß2agonist (55%), anticholinergic (30.8%), inhaled corticos-
teroids (35.5%), oral xantins (19.9%), oral corticosteroids
(7.3%) mucolitics (21.7%) oxygen therapy (4.1%). Only 6.2%
referred an adverse event with treatment. Patient satisfaction
with treatment: 62% satisﬁed because low adverse events; 61%
satisﬁed with drugs; 59.9% satisﬁed about daily life; 58.2%
showed satisfaction with effects onset; 61.4% satisﬁed with sleep
proﬁle; 59.1% showed satisfaction with symptoms control;
60.2% satisﬁed with time of doses. 44% preferred to take med-
ications once a day, 39.8% thought it’s important number of
time they had to take the drugs; 49.6% considered that the times
to take medication in a day doesn’t make it more complicated.
Males feel better symptoms control than females. Satisfaction
was higher in ß2 agonist (less adverse events, less importance on
times of dosage), anticholinergic drug (less adverse events, less
importance on times of dosage) and inhaled corticosteroids (less
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adverse events). In a multivariate analysis the variables associ-
ated with satisfaction were: ß2 agonist (p = 0.071) and males 
(p = 0.051). CONCLUSIONS: Patient satisfaction with COPD
treatment is high and is related with the low frequency of adverse
events. Satisfaction is higher in males receiving treatment with
ß2 agonist.
SURGERY
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OBJECTIVES: To estimate the cost of red blood cell (RBC)
transfusion using three different techniques, i.e. allogeneic trans-
fusion, autologous transfusion and perioperative auto-transfu-
sion, from a societal perspective for Sweden. METHODS: Data
concerning the sequence of procedures involved in the collection,
preparation and transfusion of RBCs and perioperative auto-
transfusion was collected from the Swedish National Board of
Health and Welfare, from other published sources and from
interviews with staff at ﬁve large Swedish hospitals. Direct hos-
pital costs were derived from the Southern Regional Health Care
Board and from Haemonetics Scandinavia AB. Income data on
hospital staff was derived from the Swedish federation of county
councils. Data for estimating indirect costs have been obtained
from Statistics Sweden and the National Tax Board of Sweden.
RESULTS: The cost of a 2-unit transfusion was found to be
SEK7 144 (€792) for ﬁltered allogeneic RBCs and SEK5
394(€598) for autologous RBCs for surgery patients. Transfu-
sion reactions accounted for more than 40 percent of the costs
of allogeneic RBC transfusions. The administration cost was
found to be much higher for autologous transfusions compared
to allogeneic transfusions. The cost of intraoperative erythrocyte
salvage was calculated to be SEK2567 (€285) per transfusion (>4
units). Of the three available techniques, allogeneic RBC trans-
fusion is the most common method used in Sweden. More than
99% of all donated blood is allogeneic in the case of Sweden.
CONCLUSIONS: Patients who suffer from anaemia have the
option of treatment with blood transfusion or treatment with
erythropoietic stimulating agents. From a societal perspective,
allogeneic RBC transfusions are considerably more costly than
the perceived cost at the hospitals. Allogeneic transfusion were
found to be more costly than autologous transfusions concern-
ing transfusion reactions but less costly with respect to adminis-
tration at the blood centres.
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OBJECTIVES: To estimate the cost-effectiveness of remifen-
tanil/propofol versus fentanyl/propofol as regimen of total intra-
venous anesthesia using infusion pump in Mexican Health
Sector. METHODS: An expert panel with anesthesiologists was
established to identify the medical and non-medical health
resources used to perform a general anesthesia in patients with
65kg, ASA I (American Society of Anesthesiologists) for a range
in the anesthetic time from 60 to 180 minutes and the effective-
ness accomplished with the regimens. The information gathered
from the expert panel was completed with a literature review.
Ofﬁcial unitary costs for the Mexican Institute of Social Security
(IMSS) and Hospitals from The Ministry of Health were used.
The expected cost per patient included the costs of drugs, post-
anesthetic care unit, labor costs and costs associated with adverse
events. Costs were expressed in Mexican Pesos and then con-
verted to US dollars (rate exchange 11 Mexican pesos = 1USD).
RESULTS: For the remifentanil/propofol regimen the induction
doses were 1mcg/kg remifentanil and 2mg/kg propofol; the
maintenance doses were 0.5mcg/kg/min remifentanil and 85
mcg/kg/min. For the fentanyl/propofol group the induction doses
were 3mcg/kg fentanyl and 2mg/kg propofol; the maintenance
doses were 3mcg/kg/hour fentanyl and 120mcg/kg/min. For the
median of anesthetic time, 120 minutes, the costs per anesthesia
were $1421 (129 USD) and $1644 (149 USD) for the remifen-
tanil/propofol and fentanyl/propofol regimen, respectively. The
average extubation time was 7 minutes for the regimen with
remifentanil, and 15 minutes with fentanyl. Using a visual ana-
logue scale, where 0 represents the worst value and 10 the best,
the remifentanil/propofol regimen was graded 9.6 and the fen-
tanyl/propofol 8.6. CONCLUSIONS: Regimens with remifen-
tanil/propofol dominates fentanyl/propofol techniques, since
they provide a highly effective and secure anesthesia and also
represents a signiﬁcant saving in total resources used (mainly in
use of propofol and post-anesthetic care unit) offsetting its higher
acquisition costs.
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OBJECTIVE: To evaluate cost of antibiotic therapy in patients
undergoing colorectal surgery and possible inﬂuence of post-
surgical infections on hospital costs. METHODS: We conducted
a naturalistic, retrospective study, collecting data from medical
records on patients undergoing surgery in 2002–2004, from two
Italian hospitals. Analyses were conducted from the hospital’s
point of view: cost of treatment (expressed as €/hospitalization,
values of 2005) and length of post-surgical stay as a proxy of
hospital cost are reported, with comparisons among the two hos-
pitals (HOSP1 and HOSP2). The bootstrap resampling method
(5000 samples) was applied to have more reliable results.
RESULTS: Data of 174 patients (mean age 68.3, 38–93 years,
49.4% men) was collected: 82.8% underwent surgery for malig-
nant cancer, 2.3% for benign cancer, 14.9% for other reasons.
Antibiotic therapy was applied by adopting two different guide-
lines: in HOSP1 patients were treated with 5-nitroimidazole 
and ceftazidime or cefotassime. If infections occurred,
cephalosporins, ﬂuoroquinolones, quinolones, carbapenems,
penicillines were used, according to the type of infections.
Patients from HOSP2 were preventively treated with: cefotetan
or cefoxitine, or 5-nitroimidazole + gentamicine or piperacilline
+ 5-nitroimidazole. The infected patients were treated with car-
bapenems, penicillines, cephalosporins, triazoles, amynoglico-
sides, and ﬂuoroquinolones. Thirty-eight patients (22%) were
infected, with similar frequencies in the two hospitals. Therapy
cost on average €140.59 (€0.0–816.13), with signiﬁcant differ-
ence between non infected and infected patients (97.24 vs.
€293.99, p < 0.0001). The average cost was higher in HOSP1
(€182.45 vs. €102.40, p < 0.001) while the median post-surgical
